Hemophilia
Odporúčame
Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
Critical Overview of Clinical Studies on EHL FVIII Preparations
An international team of experts recently published a comprehensive work evaluating the methodology…
Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor…
Články k téme
What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment...
Sport and Physical Activity Benefit Hemophiliacs
Sport and physical activity are beneficial for individuals with hemophilia. This statement was…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct…
Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a…
Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by…
Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the…
Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the…
Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin…
Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Authors of a recently published study attempted to determine the value of minimum and optimal…
Prihlásiť na odber spravodajcu
Kurzy k tejto téme
Najčítanejšie k tejto téme
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
Časopis k tejto téme
Súvisiace témy
Zaujímavé odkazy